Other tyrosine kinase inhibitors, such as pazopanib (PDGFRα, PDGFRβ, and VEGFR inhibitor) and olaratumab (PDGFRα inhibitor), are already approved for sarcoma treatment [80], but their metabolic effects are not widely explored (Table 2). This evidence concerns the gene PDGFRA and sarcoma.